Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01876641 · ClinicalTrials.gov registry record · Phase 1
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
A Phase 1 study, sponsored by Mohammed M Milhem.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01876641: Clinical Trial Phase 1 study, sponsored by Mohammed M Milhem.
NCT01876641 is a Phase 1 study that was terminated before completion, run by Mohammed M Milhem. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01876641, a Phase 1 study, was terminated before completion, sponsored by Mohammed M Milhem.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
Primary Outcome
Toxicity will be assessed using the NIH-NCI Common Terminology Criteria for Adverse Events, version 4.0 (CTCAEv4). Toxicity will be decided after administration of one full cycle for patients.
Interventions
- DRUG Vemurafenib + Cobimetinib, Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Why NCT01876641 stopped before completion
NCT01876641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Vemurafenib + Cobimetinib, Decitabine is the first listed.
NCT01876641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01876641 about?
NCT01876641 is a clinical study titled "Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib". The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
What is the current status of trial NCT01876641?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-10. Estimated completion is 2018-09.
What interventions are being tested in trial NCT01876641?
The interventions under investigation include: Vemurafenib + Cobimetinib, Decitabine (DRUG).
Who is sponsoring clinical trial NCT01876641?
This trial is sponsored by Mohammed M Milhem, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01876641's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia